Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT

Webcast Will Feature Key Opinion Leader, Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada

NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announces lumateperone presentations at the upcoming American Psychiatric Association (APA) Annual Meeting to be held May 1-3, 2021 and will hold a webcast on May 4, 2021.

Dr. McIntyre will describe the lumateperone data presented at APA in the context of existing medical needs in the treatment mood disorders including bipolar disorder, and “mixed features” in bipolar disorder and major depressive disorder.

The presentations at APA highlight lumateperone clinical data in bipolar depression including in patients who exhibit mixed features and patients with schizophrenia with co-morbid depression as well as detailing lumateperone’s favorable safety and tolerability profile.

The titles and presenters of the poster presentations are as follows:

Sunday, May 2, 2021, 3:30 p.m.-4:00 p.m. EDT

• “The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Bipolar Depression: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials” (P8-106), presented by Susan L. McElroy, MD.
  

Monday, May 3, 2021, 1:30 p.m.-2:00 p.m. EDT

• “Adjunctive Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial” (P11-023), presented by Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych, MBA.
• “The Efficacy of Lumateperone in Patients with Bipolar Depression With and Without Mixed Symptoms” (P11-036), presented by Roger S. McIntyre, MD.
• “Efficacy of Lumateperone (ITI-007) in Depression Symptoms Associated With Schizophrenia” (P11-087), presented by Robert E. Davis, PhD.
  

Investor webcast on, May 4, 2021

The Company will host a webcast on May 4, 2021 at 2:00 p.m. EDT. The webcast will feature Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

The live webcast and subsequent replay may be accessed by visiting the Company's website at www.intracellulartherapies.com. Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download.